Barclays analyst Etzer Darout assumed coverage of MacroGenics (MGNX) with an Overweight rating and $3 price target The firm believes MGC026 could drive share upside in 2026 due to the shortcomings of the competitor B7H3 antibody drug conjugate programs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics initiated with an Overweight at Barclays
- MacroGenics’ Strategic Shift and Lorigerlimab’s Trial Impact: A Hold Rating Amid CEO Transition and Drug Development Uncertainty
- MacroGenics price target lowered to $5 from $8 at Leerink
- MacroGenics Inc. Reports Q2 2025 Financial Results
- Closing Bell Movers: UnitedHealth jumps 10% as Berkshire, Appaloosa buy weakness